Bitter Gourd Seed Oil (Momordica charantia)

Bitter gourd seed oil (BGSO), extracted from Momordica charantia seeds, is rich in conjugated linolenic acid (CLnA), particularly α-eleostearic acid, which drives its anti-proliferative and gastroprotective effects. These bioactive fatty acids modulate apoptotic gene expression and reduce oxidative mucosal damage, making BGSO a subject of growing preclinical research.

Origin & History

Bitter gourd seed oil (BGSO) is extracted from the seeds of Momordica charantia L., a tropical vine native to Asia, Africa, and the Caribbean. The oil is typically obtained via solvent extraction methods using petroleum ether at 60°C for 6-8 hours, yielding an oil rich in conjugated fatty acids, particularly α-eleostearic acid at levels exceeding 60%.

Historical & Cultural Context

Bitter gourd seed oil from Momordica charantia has been used in folk medicine worldwide for diabetes, cancer, inflammatory diseases, jaundice, leprosy, piles, psoriasis, and rheumatism. Traditional applications also include use as a birth control and abortion agent, indicating its potent biological activity.

Health Benefits

• Anti-cancer properties: Preclinical studies show BGSO induces apoptosis in colon cancer cells through upregulation of GADD45 and p53 genes (in vitro evidence only)
• Anti-ulcer effects: Animal studies demonstrate gastroprotective effects at 10-100 mg/kg, reducing edema and mucosal damage in rats (preclinical evidence)
• Antimicrobial activity: Laboratory testing shows effectiveness against Streptococcus pyogenes at 1000 µg/mL (in vitro evidence only)
• Potential blood sugar support: While no human studies exist for the oil specifically, related bitter gourd fruit preparations show hypoglycemic effects (indirect evidence)
• Lipid metabolism: Free fatty acids from BGSO reduce triglyceride accumulation in hepatoma cells (in vitro evidence only)

How It Works

Bitter gourd seed oil exerts anti-cancer effects primarily through its high concentration of α-eleostearic acid (a conjugated linolenic acid), which upregulates pro-apoptotic genes GADD45 and p53, triggering mitochondria-mediated cell death in colon cancer cell lines. Its gastroprotective mechanism involves reduction of pro-inflammatory cytokines (TNF-α, IL-6) and inhibition of lipid peroxidation via antioxidant pathways, preserving gastric mucosal integrity. Additionally, CLnA isomers in BGSO may act as PPAR-γ ligands, influencing lipid metabolism and inflammatory signaling cascades.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted specifically on bitter gourd seed oil. Evidence is limited to preclinical studies, including in vitro cancer cell research and rat models for anti-ulcer effects at 10-100 mg/kg doses. Human studies exist only for other forms of bitter gourd, such as fruit powder at 2-2.5 g/day showing blood glucose effects.

Clinical Summary

Current evidence for bitter gourd seed oil is limited to in vitro and animal models, with no published randomized controlled trials in humans. In vitro studies demonstrate dose-dependent apoptosis induction in HT-29 colon cancer cells via GADD45 and p53 upregulation, though these findings have not been replicated in human subjects. Animal studies using rat models report significant gastroprotective effects at doses of 10–100 mg/kg, including reduced gastric edema and mucosal lesion scores compared to controls. The totality of evidence is preliminary; human pharmacokinetic and efficacy data are currently absent, warranting caution before drawing clinical conclusions.

Nutritional Profile

Bitter Gourd Seed Oil (BGSO) is a lipid-rich extract with a distinctive fatty acid profile dominated by conjugated linolenic acid (CLnA) isomers, particularly alpha-eleostearic acid (cis-9, trans-11, trans-13 octadecatrienoic acid) comprising approximately 50-60% of total fatty acids — a rare conjugated trienoic fatty acid also found in tung oil. Additional fatty acids include linoleic acid (omega-6, ~15-20%), oleic acid (omega-9, ~10-15%), stearic acid (~5-8%), and palmitic acid (~4-6%). The oil contains no significant protein, fiber, or carbohydrate content as it is a refined seed oil extract. Micronutrient content includes tocopherols (primarily gamma-tocopherol, ~200-400 mg/kg oil), functioning as endogenous antioxidants that contribute to oil stability. Bioactive compounds include momordicin-related triterpenoids carried in trace residual amounts from seed extraction, and phytosterols (beta-sitosterol being predominant, estimated ~1,000-2,500 mg/kg), which may contribute to cholesterol-modulating effects. The conjugated trienoic fatty acid alpha-eleostearic acid is considered the primary bioactive component responsible for documented biological activities. Bioavailability note: Alpha-eleostearic acid undergoes partial conversion to rumenic acid (CLA isomer) during intestinal absorption in mammals, which may partially mediate its bioactivity; absorption efficiency is enhanced when consumed with other dietary fats. Cold-pressed extraction preserves higher bioactive compound concentrations compared to solvent-extracted variants.

Preparation & Dosage

No clinically studied dosages exist for bitter gourd seed oil in humans. Preclinical studies used 10-100 mg/kg body weight in rats. Related bitter gourd fruit powder has been studied at 2-2.5 g/day in humans. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Alpha-lipoic acid, Chromium picolinate, Cinnamon extract, Turmeric, Black pepper extract

Safety & Interactions

Human safety data for isolated bitter gourd seed oil supplements is largely lacking, though the whole fruit of Momordica charantia is generally consumed safely as food across Asia and Africa. Animal studies suggest hepatotoxic potential at high doses, and the hypoglycemic properties of Momordica charantia compounds may potentiate blood glucose-lowering medications such as metformin or insulin, risking additive hypoglycemia. BGSO is contraindicated during pregnancy due to documented uterotonic and abortifacient effects of Momordica charantia constituents in animal models. Individuals with G6PD deficiency should exercise caution, as favism-like reactions have been reported with related Momordica preparations.